Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Overview of attention for article published in Journal of Hematology & Oncology, September 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy: 2 policy sources
twitter: 5 X users

f1000: 1 research highlight platform

Readers on

mendeley: 142 Mendeley

Summary Policy documents X Research highlights

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 105,334 followers.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses [Sep 29, 2017] Verstovsek et al. J Hematol Oncol. https://t.co/3J3NAwZzfU #mpnsm support Tx for int-2 or high-risk MF, regardless of anemia or tra

12 Sep 2019

Reply Repost Favourite

18 Feb 2019

Reply Repost Favourite

@drharshvardhan @Narendramodi_PM @aiims_newdelhi @rashtrapatibhvn Check for it. https://t.co/qLFbd5vHOn

07 Jun 2018

Reply Repost Favourite

Are you an oncologist or hematologist, treating patients with myelofibrosis? Read our open access research: https://t.co/UyZKCo8mjA #SN_GrandChallenges https://t.co/Wors13TFRs

01 Jun 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.